Tumor Microenvironment Reprogramming — PatSnap Eureka
Tumor Microenvironment Reprogramming: TAM Depletion, MDSC Suppression & M2-to-M1 Polarization
TAMs constitute 30–50% of stromal cells in advanced solid tumors, driving immunosuppression across breast, pancreatic, lung, and six other cancer types. PatSnap Eureka maps the full therapeutic pipeline—from CSF-1R inhibitors in clinical trials to nanomedicine platforms in preclinical development.
Why the Tumor Microenvironment Is the Next Frontier in Immuno-Oncology
The tumor microenvironment (TME) is increasingly recognized as a central determinant of cancer progression, therapy resistance, and immunotherapy efficacy. Research published via NIH-funded programs and patent literature retrieved by PatSnap Eureka consistently positions tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) as the dominant immunosuppressive drivers across most solid tumor types.
Monocyte-derived macrophages recruited to the tumor site undergo M2 polarization under the influence of tumor-derived signals including IL-4, IL-10, IL-13, CSF-1, and TGF-β. This transitions them from potential tumor suppressors into pro-tumoral effectors that promote angiogenesis, metastasis, extracellular matrix remodeling, and T cell exclusion. High TAM infiltration density is associated with poor prognosis across breast, pancreatic, colorectal, lung, ovarian, liver, and gastric cancers.
The convergence of single-cell transcriptomics, nanotechnology, and targeted pharmacology has catalyzed a broad therapeutic pipeline. PatSnap's life sciences intelligence platform tracks this pipeline across four primary molecular targeting axes: the CSF-1/CSF-1R axis, CD47–SIRPα "don't-eat-me" signaling, PD-1/PD-L1 on TAMs, and TREM2 on immunosuppressive TAM populations.
For MDSCs, the MAPK/ERK pathway, fatty acid oxidation (FAO), PMN-MDSC expansion pathways, and STAT3 signaling represent the primary molecular vulnerabilities identified across more than 40 retrieved papers. The NCI's immunotherapy research agenda aligns closely with these mechanistic targets.
Six Pharmacological Approaches to TME Reprogramming
From clinically advanced CSF-1R inhibitors to preclinical nanomedicine platforms, the TME pipeline spans small molecules, biologics, metabolic agents, and epigenetic modulators.
CSF-1R Inhibition — TAM Depletion & Recruitment Blockade
CSF-1/CSF-1R blockade is the most mature pharmacological approach to TAM depletion. CSF-1R inhibitors reduce monocyte-to-TAM differentiation and promote elimination of established M2-polarized macrophages. Anti-CD40 mAb combined with CSF-1R inhibition induced a polyfunctional inflammatory TAM subset co-secreting TNF-α, IL-6, and IL-12 in murine melanoma (Yale University, 2018). Referenced in clinical trial contexts in combination with anti-PD-1/PD-L1 therapy.
Backbone for combination checkpoint strategiesAnti-CD47 / Phagocytosis Enhancement
Tumor cells exploit CD47 expression to evade TAM-mediated phagocytosis. ZL-1201 (Zai Lab) is a differentiated anti-CD47 antibody with improved hematologic safety versus 5F9 benchmark, enhancing phagocytosis in combination with rituximab, trastuzumab, and cetuximab. CD47 blockade reactivates TAM-intrinsic tumoricidal capacity through restored antibody-dependent cellular phagocytosis (ADCP), operating independently of polarization reprogramming.
Synergistic with standard-of-care antibodiesSmall Molecule Kinase Inhibitors & Metabolic Reprogramming
The most pharmacologically diverse cluster. BMS-794833 (Fred Hutchinson) suppresses triple-negative breast cancer via FAK and other pathways. MAO-A inhibitors (UCLA) show synergistic tumor suppression with anti-PD-1. CDDO-Me (Dartmouth) suppresses IL-10 and VEGF while upregulating HLA-DR and CD80. Plinabulin increases M1-like/M2-like TAM ratio in MC38 colon cancer. FAO inhibitors (perhexiline, trimetazidine) re-polarize M2 macrophages.
Most diverse mechanistic cluster in datasetEpigenetic Modulators — HDAC & DNA Methylation Inhibitors
HDAC inhibitor trichostatin A (TSA) at low dose reshaped the tumor immune microenvironment by modulating TAM and MDSC suppressive activity, potentiating anti-PD-L1 therapy (Soochow University, 2021). Combined 5-aza-2'-deoxycytidine + TSA reprogrammed M2-type TAMs into M1-like phenotype via upregulation of miR-7083-5p, with conditioned medium sensitizing tumor cells to paclitaxel (Kyungpook National University, 2022).
Sensitizes tumors to paclitaxel via miR-7083-5pNanomedicine Platforms for Targeted TAM Repolarization
Nanoparticle-based delivery improves TAM-targeting selectivity and enables co-delivery of synergistic payloads. A pH-sheddable PEG corona micelle system (Sun Yat-sen University, 2020) co-delivers STAT6 inhibitor and IKKβ siRNA, activating selectively in the acidic TME. Mannose-modified macrophage-derived microparticles (Met@Man-MPs) loaded with metformin induce M1 repolarization and increase CD8+ T cell infiltration while reducing MDSCs and Tregs.
Avoids M1/M2 imbalance in normal organsBiological Agents Targeting MDSC Suppression
Immunostimulatory RNA (poly(I:C)) reprogrammed MDSCs in KPC pancreatic tumor-bearing mice via type I interferon induction (LMU Munich, 2019). Prim-O-glucosylcimifugin (Traditional Chinese Medicine-derived) enhanced PD-1 inhibitor efficacy in melanoma by targeting PMN-MDSCs. MDM2 inhibitor APG-115 (Ascentage Pharma — in clinical development) activates p53 in myeloid cells, suppressing M2 polarization and augmenting anti-PD-1 immunotherapy.
APG-115 in clinical development (Ascentage Pharma)Pipeline Distribution & Institutional Activity Signals
Visualizing therapeutic modality distribution by development stage and the institutional landscape driving TME reprogramming research.
TME Therapeutic Modalities by Development Stage
CSF-1R inhibition and anti-CD47 are the most clinically advanced; nanomedicine and epigenetic approaches remain predominantly preclinical.
Key Molecular Targets by Research Prominence
CSF-1/CSF-1R is the most frequently cited target; TREM2, MAO-A, and PI3Kγ represent emerging mechanistic frontiers.
Key Molecular Targets & Mechanistic Findings
Deep-dive findings on the most actionable targets identified across 80+ retrieved publications, from established clinical axes to novel druggable enzymes.
CSF-1/CSF-1R — Most Clinically Advanced TAM Axis
The most frequently cited recruitment and survival axis for TAMs across the dataset. Inhibition of CSF-1R was referenced in clinical trial contexts by multiple independent groups and positioned as a backbone for combination strategies with anti-PD-1/PD-L1 therapy. Anti-CD40 mAb + CSF-1R inhibition reduced M2-like TAM subsets while inducing polyfunctional inflammatory TAMs co-secreting TNF-α, IL-6, and IL-12 (Yale University, 2018). PatSnap Analytics tracks CSF-1R combination trial activity in real time.
TREM2 — Immunosuppressive TAM Marker (Pionyr Immunotherapeutics)
Identified by Pionyr Immunotherapeutics as a marker of immunosuppressive TAMs correlated with CD8+ T cell exhaustion. TREM2+ TAMs are enriched in ovarian cancer and correspond to worse recurrence-free survival. Fc-enhanced anti-TREM2 mAb therapy depleted and modulated TAM populations, promoting CD8+ TIL infiltration. TREM2 represents a convergence point between TAM exhaustion biology and immunotherapy resistance.
MAO-A — Novel Druggable TAM Immunosuppressive Enzyme (UCLA)
Monoamine oxidase A is an inducible enzyme in both mouse and human TAMs, with established CNS-targeted MAOIs repurposed for TAM reprogramming. High intratumoural MAOA expression correlates with poor patient survival across broad cancer types. The MAO-A/serotonin-kynurenine metabolic axis in TAMs represents a pharmacologically tractable immunosuppressive pathway distinct from canonical checkpoints. MAOI + anti-PD-1 combination showed synergistic tumor suppression.
STAT6 / IKKβ / NF-κB — Nanodrug Co-Inhibition Strategy
Co-inhibition of STAT6 (M2 transcription driver) and IKKβ (NF-κB pathway activator) via nanodrug co-delivery was shown to be mechanistically synergistic for M2-to-M1 repolarization without systemic inflammatory side effects (Sun Yat-sen University, 2020). The pH-sheddable PEG corona system with M2-targeting peptides selectively activated in the acidic TME, avoiding M1/M2 imbalance in normal organs.
Who Is Driving TME Reprogramming Research?
Activity in this dataset is predominantly literature-driven (academic papers) rather than patent-driven. The following institutional profiles emerge from 80+ retrieved results.
| Institution / Assignee | Region | Primary Focus Areas | Stage Signal |
|---|---|---|---|
| Pionyr Immunotherapeutics | US (South San Francisco) | TREM2-targeted TAM depletion; Fc-enhanced anti-TREM2 mAb | Commercial-Stage |
| Zai Lab (US) LLC | US | Anti-CD47 antibody ZL-1201; ADCP enhancement; hematologic safety improvement | Clinical Candidate |
| Ascentage Pharma | China/US | MDM2 inhibitor APG-115; p53 activation in myeloid cells; anti-PD-1 synergy | In Clinical Development |
| UCLA (two related papers) | US | MAO-A as TAM immunosuppressive enzyme; MAOI repurposing; serotonin-kynurenine axis | Preclinical / Repurposed |
| Fred Hutchinson Cancer Research Center | US | Phenotypic kinase screening; BMS-794833 in TNBC; FAK-independent repolarization | Preclinical |
| Yale University | US | Myeloid combination immunotherapy; anti-CD40 + CSF-1R dual strategy | Preclinical |
| West China Hospital / Sichuan University | China | MAPK/ERK inhibitors for MDSC in-situ depletion; PMN-MDSC apoptosis | Preclinical |
| Sun Yat-sen University | China | M2-targeting pH-sheddable nanodrug; STAT6 inhibitor + IKKβ siRNA co-delivery | Preclinical |
| Huazhong University of Science & Technology | China | Metformin-loaded macrophage-derived microparticles; Met@Man-MPs; anti-PD-1 boosting | Preclinical |
| University of Groningen | Europe (Netherlands) | Metabolic drug repolarization; FAO inhibitors; CB-839 glutaminolysis; HX531 PPAR antagonism | Preclinical |
Track Assignee Activity & Patent Filings in Real Time
Use PatSnap Eureka to monitor Pionyr, Zai Lab, Ascentage, and emerging academic spinouts filing in the TME space.
What Has Reached the Clinic — and What Hasn't Yet
Retrieved results provide several signals of clinical translation, though the dataset is predominantly preclinical. CSF-1R inhibitors are referenced in multiple reviews as having entered clinical trials, either as monotherapy or in combination with checkpoint inhibitors, across solid tumor indications. Specific trial identifiers and outcome results are not resolvable from the retrieved abstracts.
APG-115 (MDM2 inhibitor, Ascentage Pharma) is explicitly described as "in clinical development" at the time of the 2019 publication, with preclinical synergy data with PD-1 blockade presented as rationale for combination trial design. Plinabulin is described as a "clinical-stage novel agent," with the University Hospital Basel study demonstrating macrophage-dependent antitumor efficacy in MC38 colon cancer, with anti-tumor efficacy preserved in T cell-deficient mice.
Anti-PD-1-based therapies in metastatic sarcoma with angiogenesis inhibitors are reported with retrospective clinical data from 24 patients; median progression-free survival of 7.59 months was reported in a cohort where TAM phenotype dynamics had been previously characterized (Tianjin Medical University Cancer Institute, 2021). ClinicalTrials.gov lists active TME-targeting combination trials for independent verification.
MAOIs are clinically approved for neurological disorders, with UCLA studies providing preclinical rationale for oncological repurposing in combination with anti-PD-1, but no clinical oncology trial data is present in the retrieved dataset. The European Medicines Agency regulatory landscape for myeloid-targeting agents remains an open monitoring signal. PatSnap customers in pharma use Eureka to track exactly these translational gaps.
Important note: The dataset contains no Phase III data, no regulatory submission signals, and no approval-level evidence for any TAM- or MDSC-targeting agent. All clinical translation signals are derived from abstracts describing earlier-phase activity or preclinical rationale.
Tumor Microenvironment Reprogramming — Key Questions Answered
TAMs are estimated to constitute 30–50% of stromal cells in advanced solid tumors, with high infiltration density associated with poor prognosis across breast, pancreatic, colorectal, lung, ovarian, liver, and gastric cancers.
CSF-1R inhibition represents the most clinically advanced TAM-depletion strategy identified in the dataset. CSF-1R inhibitors reduce monocyte-to-TAM differentiation and promote the elimination of established M2-polarized macrophages, and are referenced in clinical trial contexts in combination with checkpoint inhibitors.
Tumor cells exploit CD47 expression to evade TAM-mediated phagocytosis. Blockade via anti-CD47 antibodies (e.g., ZL-1201) restores antibody-dependent cellular phagocytosis (ADCP), reactivating TAM-intrinsic tumoricidal capacity independently of polarization reprogramming, and is positioned as synergistic with therapeutic antibodies such as rituximab, trastuzumab, and cetuximab.
Monoamine oxidase A (MAO-A) is an inducible enzyme in both mouse and human TAMs. High intratumoural MAOA expression correlates with poor patient survival across broad cancer types. MAO-A-deficient mice exhibited reduced TAM immunosuppressive function, and MAOI combined with anti-PD-1 showed synergistic tumor suppression in preclinical models. The MAO-A/serotonin-kynurenine metabolic axis in TAMs represents a pharmacologically tractable immunosuppressive pathway distinct from canonical checkpoints.
Retrieved results highlight the MAPK/ERK pathway, fatty acid oxidation (FAO), polymorphonuclear MDSC (PMN-MDSC) expansion pathways, and STAT3 signaling as primary molecular vulnerabilities. MAPK inhibitors such as ERK1/2 inhibitor SCH772984 and JNK inhibitor SP600125 significantly increased apoptosis of PMN-MDSCs and M-MDSCs in tumor tissue with limited peripheral toxicity.
The combination of 5-aza-2'-deoxycytidine (a DNA methylation inhibitor) and trichostatin A (an HDAC inhibitor) was shown to reprogram M2-type TAMs into an M1-like phenotype, acting in part through upregulation of miR-7083-5p. Conditioned medium from treated macrophages sensitized tumor cells to paclitaxel. HDAC inhibitor TSA alone at low dose also modulated TAM and MDSC suppressive activity, potentiating anti-PD-L1 therapy.
Still have questions about the TME drug pipeline? Let PatSnap Eureka search 2B+ data points to answer them.
Ask PatSnap Eureka Your TME QuestionAccelerate Your TME Drug Discovery with AI-Powered Patent & Literature Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map therapeutic pipelines, track assignee activity, and identify whitespace in immuno-oncology.
References
- Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity — Yale University, 2018
- Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1 — Shanghai Jiao Tong University, 2021
- Current Strategies to Target Tumor-Associated-Macrophages — University of Santiago de Compostela, 2019
- CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity — Zai Lab, 2022
- Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function — Ohio State University, 2021
- Targeting TREM2 on tumor-associated macrophages enhances immunotherapy — Pionyr Immunotherapeutics, 2021
- Targeting the MDSCs of Tumors In Situ With Inhibitors of the MAPK Signaling Pathway — West China Hospital/Sichuan University, 2021
- Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy — Beijing Normal University, 2020
- Targeting Tumor-Associated Macrophages in Cancer Immunotherapy — Duke University Medical Center, 2021
- Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies — University of Southampton, 2021
- Polypharmacological Re-programming of Tumor-associated Macrophages Restores Antitumor Immunity — Fred Hutchinson Cancer Research Center, 2021
- Targeting monoamine oxidase A-regulated TAM polarization for cancer immunotherapy — UCLA, 2020
- Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy — UCLA, 2021
- CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages — Dartmouth/Geisel School of Medicine, 2016
- CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer — Michigan State University, 2020
- Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles — Huazhong University of Science and Technology, 2021
- Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization — University Hospital Basel, 2021
- Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs — University of Groningen, 2021
- Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer — LSU Health Sciences Center, 2016
- HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression — Soochow University, 2021
- Epigenetic therapy reprograms M2-type tumor-associated macrophages into an M1-like phenotype by upregulating miR-7083-5p — Kyungpook National University, 2022
- M2-Like Tumor-Associated Macrophage-Targeted Codelivery of STAT6 Inhibitor and IKKβ siRNA — Sun Yat-sen University, 2020
- 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells — 2015
- Emerging Nanoparticle Strategies for Modulating Tumor-Associated Macrophage Polarization — Shanghai Jiao Tong University, 2021
- Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer — LMU Munich, 2019
- Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells — Tianjin International Joint Academy of Biomedicine, 2019
- MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity — Ascentage Pharma, 2019
- In Vivo Inhibition of c-MYC in Myeloid Cells Impairs Tumor-Associated Macrophage Maturation — CNIC Spain, 2012
- Metabolism drives macrophage heterogeneity in the tumor microenvironment — University of Michigan, 2022
- Reprograming of Tumor-Associated Macrophages in Breast Tumor-Bearing Mice under Chemotherapy by Targeting Heme Oxygenase-1 — Seoul National University, 2021
- Polyamine Depletion Strategies in Cancer: Remodeling the Tumor Immune Microenvironment — University of Maryland Baltimore County, 2022
- The efficacies and biomarker investigations of anti-PD-1-based therapies for metastatic bone and soft tissue sarcoma — Tianjin Medical University Cancer Institute, 2021
- National Institutes of Health (NIH) — Immunotherapy Research Programs
- ClinicalTrials.gov — TME-Targeting Combination Trials Registry
- National Cancer Institute (NCI) — Immunotherapy Research Agenda
- European Medicines Agency (EMA) — Myeloid-Targeting Agent Regulatory Landscape
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.